- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01947569
Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy
Autologous Co-stimulation-impaired Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy: A Sequential Open Label Phase IB Safety Assessment/ Randomized, Double-blind Phase IIA Efficacy Trial to Maintain and Improve Functional Beta Cell Mass in New Onset Disease T1DM Patients
Phase IB will evaluate the safety of autologous, ex vivo-engineered, co-stimulation impaired dendtritic cells to maintain and improve functional residual beta cell mass in new onset Type I Diabetes Mellitus (T1DM) patients. Efficacy measures will be collected and summarized.
Phase IIA will evaluate the safety and efficacy of 3 randomized treatment groups in new onset T1DM patients to assess if the antisense DNA-treated co-stimulation-impaired immunoregulatory dendritic cells (iDC) will safely preserve and/or increase B-cell mass resulting in improvement and/or normalization of blood glucose levels and glycated hemoglobin A1c.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Anticipé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Orville G. Kolterman, MD
- Numéro de téléphone: 7242085707
- E-mail: okolterman@alumnistandford.edu
Sauvegarde des contacts de l'étude
- Nom: Peter Gregoire, MBA
- Numéro de téléphone: 7242085707
- E-mail: pgregoire@futurelifesourcesllc.org
Lieux d'étude
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15213
- UPMC
-
Chercheur principal:
- Mary Korytokowski, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:(both open label phase IB safety and Phase IIA study):
- Patients with new onset T1DM (>18 years of age for the phase IB and then >16 (first 10 subjects), >12 years of age for the second 10 subjects, > 8 years for the next 10 subjects and, finally, >8 years of age for the remainder of the phase IIA patients) within 6 months of diabetes mellitus diagnosis.
- Evidence of decreased β-cell function as measured by C-peptide and blood glucose levels consistent with impaired glucose tolerance.
- Evidence of at least one high-risk HLA haplotype.
- Evidence of at least one diabetes-related autoantibody (e.g. IA-2, GAD, ZnT8) ,
- Adequate immune competence as assessed by immunoreactivity to alloantigens in mixed leukocyte culture and reactivity to viral antigens (CEF Pool Assay) in vitro.
- Normal hematologic, liver and kidney function.
- Female participants of childbearing potential in this study must agree to use an effective form of birth control during study participation. Reliable and effective forms of birth control include: true abstinence, intrauterine device (IUD), hormonal-based contraception, double-barrier contraception [condom or occlusive cap (diaphragm or cervical cap) with spermicide], or surgical sterilization (vasectomy for male partner, tubal ligation or hysterectomy). Sexually active male participants must agree to use an effective form of birth control such as condoms.
Exclusion Criteria:(both open label phase IB safety and Phase IIA study):
- Enrollment or history of enrollment in a drug, or biologic therapy study sponsored by TrialNet.
- A significant history or current evidence of cardiac disease, uncontrolled hypertension, serious arrhythmias.
- Evidence of active infection requiring antibiotic therapy.
- History of other concurrent significant medical diseases.
- Pregnant or lactating women.
- Patients requiring chronic systemic corticosteroids.
- Any other immune disorder including but not limited to other autoimmune diseases, HIV, HBV, HCV, HPV, HSV positivity.
- Impaired renal function with a creatinine level > 1.5.
- Administration of the following therapies while patients are undergoing treatment on this protocol: i) radiation therapy; ii) chemotherapy; iii) corticosteroids (except when administered in life-threatening circumstances); iv) other particle or cell-based therapies; v) other biologic therapies; vi) other therapies aimed at modulating the immune system; vii) other endocrine-related therapies, hormone replacement (other than thyroxine and contraceptive), glucoregulation.
- A hemaglobinopathy known to interfere with the ability to accurately determine HbA1c.
- No prior radiation therapy, immunotherapy, or chemotherapy.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: iDC recipients
iDC cells modified by in vitro engineering.
|
|
Comparateur actif: Control DC recipients
DC cells which have not been modified.
|
|
Comparateur placebo: Placebo recipients
Saline injections.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
The incidence of treatment-emergent adverse events.
Délai: Month 12
|
Month 12
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
2-hour area under the curve (AUC) average of C-peptide at 12 months after completion of administration of assigned therapy (Protocol Month 15).
Délai: 12 Months
|
12 Months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- DV-0100-100
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Biological
-
GlaxoSmithKlineComplétéInfections, PapillomavirusTaïwan, Thaïlande, Brésil
-
GlaxoSmithKlineComplétéRougeole | Rubéole | Oreillons | VaricelleInde
-
GlaxoSmithKlineComplétéInfections, PapillomavirusÉtats-Unis, Canada
-
GlaxoSmithKlineComplétéHépatite B | Tétanos | Diphtérie | Coqueluche acellulaire | Poliomyélite | Haemophilus influenzae de type bFinlande
-
Tianjin Medical University Cancer Institute and...RecrutementCancer de l'œsophageChine
-
GlaxoSmithKlineComplétéRougeole | Rubéole | Oreillons | Vaccin rougeole-oreillons-rubéoleÉtats-Unis, Porto Rico
-
GlaxoSmithKlineThe PATH Malaria Vaccine Initiative (MVI)Complété
-
Shanghai Institute Of Biological ProductsComplété
-
Jiangsu Province Centers for Disease Control and...ComplétéEffet indésirable et immunogénicité du vaccinChine